Metformin
Metformin
ATC Code: A10BA02Repaglinide
ATC Code: A10BX02Nateglinide
ATC Code: A10BX03News Source
Gliclazide Preferred Over GlucoNorm
News Date
Brief Description
Gliclazide MR [DiaMicron MR] preferred over GlucoNorm for efficacy, tolerability and cost per CADTH report.
The CADTH cost-effectiveness analysis, based on the results of the MTC meta-analysis, indicated that sulfonylureas [GLIZLAZIDE MR/DIAMICRON MR] were the most cost effective second-line therapy in patients inadequately controlled on metformin monotherapy, despite higher rates of overall and severe hypoglycemia relative to other oral antidiabetes drugs. Favourable cost-effectiveness results for sulfonylureas are attributable to:
- low price relative to other classes of drugs, especially newer agents and insulin
- minimal differences in glycemic control between active drug classes
- low absolute risk of severe hypoglycemia requiring health care resource use in patients
using sulfonylureas
Other active treatments [i.e. GLUCONORM] were associated with unfavourable cost-effectiveness
estimates (i.e., they were dominated or demonstrated very high ICURs) when compared with
the next least costly treatment.
No comments so far